Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting IDH1/IDH2 mutations in gliomas.

Current opinion in neurology - 1 Dec 2022

de la Fuente Macarena I

Abstract excerpt

PURPOSE OF REVIEW: Somatic point mutations in the metabolic enzyme isocitrate dehydrogenase (IDH) are a defining feature of the majority of WHO grade 2-3 diffuse glioma and the most powerful positive prognostic factor for survival in gliomas. The purpose is to review experimental therapeutic approaches targeting IDH mutations in gliomas including small-molecule inhibitors, immunotherapies, and agents targeting...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Cancer, Hypoxia, and Metabolism
Share to Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Glioma Diagnosis and Treatment

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Neuroblastoma Research and Treatments

Source

Identifiers

PMID: 36367045
DOI: 10.1097/WCO.0000000000001111

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting IDH1/IDH2 mutations in gliomas.PMID 36367045Read ↗

Therapies for IDH-Mutant Gliomas.Semantic proximity Read ↗

Advances in the treatment of IDH-mutant gliomas.Semantic proximity Read ↗

IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment.Semantic proximity Read ↗

IDH1 and IDH2 mutations in gliomas.Semantic proximity Read ↗

Isocitrate dehydrogenase mutations in gliomas: A review of current understanding and trialsSemantic proximity Read ↗

Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-MutationsSemantic proximity Read ↗

The Role of Mutant IDH Inhibitors in the Treatment of Glioma.Semantic proximity Read ↗

IDH Mutations in Glioma: Double-Edged Sword in Clinical Applications?Semantic proximity Read ↗

Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.Semantic proximity Read ↗

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical ImplicationsSemantic proximity Read ↗

IDH Mutations in Glioma: Molecular, Cellular, Diagnostic, and Clinical ImplicationsSemantic proximity Read ↗

IDH-mutant gliomas in children and adolescents - from biology to clinical trialsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.